Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Pharmacoeconomics|August 9, 2021
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and AssessmentMichael Schlander, Karla Hernandez-Villafuerte, Chih-Yuan Cheng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 20, 2019
Cost-Effectiveness of Colorectal Cancer Screening Strategies-A Systematic ReviewTao Ran, Chih-Yuan Cheng, Benjamin Misselwitz, et al.
International Journal of Cancer|October 3, 2024
Anxiety and depression in cancer patients and survivors in the context of restrictions in contact and oncological care during the COVID-19 pandemicDaniela Doege, Julien Frick, Rachel D Eckford, et al.
European Child & Adolescent Psychiatry|September 19, 2018
The cost incurred by victims of bullying from a societal perspective: estimates based on a German online survey of adolescentsVanessa Jantzer, Michael Schlander, Johann Haffner, et al.
Orphanet Journal of Rare Diseases|January 8, 2020
Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN networkJean-Michel Heard, Charlotte Vrinten, Michael Schlander, et al.
International Journal of Cancer|March 3, 2026
Toward a validated European instrument to measure the socioeconomic impact of cancerJasper Ubels, Julie M Vancoppenolle, Josephine Tetteh, et al.
Pharmacoeconomics|November 11, 2018
Determining Value in Health Technology Assessment: Stay the Course or Tack Away?J Jaime Caro, John E Brazier, Jonathan Karnon, et al.
Applied Health Economics and Health Policy|August 9, 2018
Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and RebatesJaime Espin, Michael Schlander, Brian Godman, et al.
Health Services Research|March 16, 2007
Treatment for ADHD: is more complex treatment cost-effective for more complex cases?E Michael Foster, Peter S Jensen, Michael Schlander, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|December 8, 2021
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2]Domenico Moro, Michael Schlander, Harry Telser, et al.
Pageof 7